Invention Grant
US07696218B2 Substituted 1,3-dialkyl-2,4-dioxo-6-(arylamino)-1,2,3,4-tetrahydropyrimidine-5-hydroxamic acid inhibitors of MAPK/ERK kinase
有权
取代的MAPK / ERK激酶的1,3-二烷基-2,4-二氧代-6-（芳基氨基）-1,2,3,4-四氢嘧啶-5-异羟肟酸抑制剂
- Patent Title: Substituted 1,3-dialkyl-2,4-dioxo-6-(arylamino)-1,2,3,4-tetrahydropyrimidine-5-hydroxamic acid inhibitors of MAPK/ERK kinase
- Patent Title (中): 取代的MAPK / ERK激酶的1,3-二烷基-2,4-二氧代-6-（芳基氨基）-1,2,3,4-四氢嘧啶-5-异羟肟酸抑制剂
-
Application No.: US11876635Application Date: 2007-10-22
-
Publication No.: US07696218B2Publication Date: 2010-04-13
- Inventor: Qing Dong , Stephen W. Kaldor
- Applicant: Qing Dong , Stephen W. Kaldor
- Applicant Address: US CA San Diego
- Assignee: Takeda San Diego, Inc.
- Current Assignee: Takeda San Diego, Inc.
- Current Assignee Address: US CA San Diego
- Agent David Stemerick; Mitchell R. Brustein
- Main IPC: A61K31/505
- IPC: A61K31/505
Abstract:
Compounds of the substituted 1,3-dialkyl-2,4-dioxo-6-(arylamino)-1,2,3,4-tetrahydropyrimidine-5-hydroxamic acids, show below: wherein the variables are as defined herein, and pharmaceutical compositions thereof, are provided for use as inhibitors of with MEK kinase.
Public/Granted literature
- US20080125437A1 MAPK/ERK KINASE INHIBITORS Public/Granted day:2008-05-29
Information query
